Foslevodopa–foscarbidopa for treating advanced Parkinson’s with motor symptoms (TA934)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 November 2023
Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 October 2019
Gosuranemab for treating progressive supranuclear palsy [ID1607]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Levodopa, carbidopa monohydrate and entacapone intestinal gel for treating the symptoms of advanced Parkinson’s disease [ID4005]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease TS ID 11941Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Deutetrabenazine for treating tardive dyskinesia [TSID12159]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Levodopa inhaled for patients with Parkinson’s disease who experience ‘off’ episodes (motor response fluctuations) [TSID8778]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC